Arcutis Biotherapeutics【ARQT】銘柄情報

Arcutis Biotherapeutics Inc (ARQT) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

27.04

( 3.72% )

買値

27.04

売値

27.06

出来高

920,613

平均取引量 (3 か月)

US$ 1,707,807

財務取引量

US$ 24,565,220

26.10 日の範囲 27.17

13.06 52 週間の範囲 31.77

時価総額

3.382B

企業価値

3.119B

前日終値

26.07

始値

26.30

時刻

27.0249

最終取引時間

01:00:15

VWAP

26.6835

歳入

415.62M

純利益

-2.38M

発行済株式数

125,083,374

浮動株比率 (%)

74.01%

機関投資家保有比率 (%)

108.63%

配当利回り

PER

-1.39k

株価売上高倍率 (PSR)

7.77

1 株当たり利益 (EPS)

-0.02

ベータ

1.48

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam se... Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.arcutis.com

本社

Westlake Village, United States

設立

2026

Arcutis Biotherapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker ARQT. The last closing price for Arcutis Biotherapeutics was US$26.07. Over the last year, Arcutis Biotherapeutics shares have traded in a share price range of US$ 13.06 to US$ 31.77.

Arcutis Biotherapeutics currently has 125,083,374 shares in issue. The market capitalisation of Arcutis Biotherapeutics is US$3.38 billion. Arcutis Biotherapeutics has a price to earnings ratio (PE ratio) of -1,391.22.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S...

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.11	-0.405156537753	27.15	27.21	25.25	1195109	26.00220878	CS
4	5.14	23.4703196347	21.9	28.38	21.72	1933876	25.85734621	CS
12	2.74	11.2757201646	24.3	28.38	19.295	1777621	23.12853399	CS
26	-2.33	-7.93326523664	29.37	30.75	19.295	1560083	24.14673694	CS
52	13.29	96.6545454545	13.75	31.77	13.06	1803769	22.81987	CS
156	17.7	189.507494647	9.34	31.77	1.76	2452962	12.14832946	CS
260	1.85	7.34418420008	25.19	31.77	1.76	1702556	12.68075164	CS